| INSTITUTIONAL-INVESTOR |
INSTITUTIONAL-INVESTOR |
92%
|
the shares of Common Stock to be sold and issued by the Company to the Institutional Investor under the ELOC Agreement |
| WOODWARD |
WOODWARD |
92%
|
Our future revenue stream will substantially come from one customer, Woodward, and will solely be dependent on that certain manufacturing and supply agreement, dated January 12, 2026, by and among Na… |
| NAPO-PHARMACEUTICALS-INC |
NAPO-PHARMACEUTICALS-INC |
90%
|
On March 6, 2026, the Company and Napo Pharmaceuticals, Inc., the Company’s wholly-owned subsidiary (“Napo” and together with the Company, the “Borrower”), entered into an amendment (the “2021 Note A… |
| WOODWARD-SPECIALTY-LLC |
WOODWARD-SPECIALTY-LLC |
90%
|
Woodward purchases existing product inventory from Napo pursuant to the terms of the manufacturing and supply agreement. |
| CAH |
Cardinal Health, Inc. |
85%
|
s promise to transfer Mytesi to specialty pharmacies based on specified payment and shipping terms as outlined in the Exclusive Distribution Agreement entered into by the Company and Cardinal Health,… |
| CAH |
Cardinal Health, Inc. |
85%
|
Reciprocal relationship from CAH graph: Reciprocal relationship from JAGX graph: Reciprocal relationship from CAH graph: Reciprocal relationship from JAGX graph: s promise to transfer Mytesi to speci… |
| FUTURE-PAK-LLC |
FUTURE-PAK-LLC |
80%
|
Future Pak is an affiliate of Woodward and is a party to the manufacturing and supply agreement with Napo. |
| IRWD |
Ironwood Pharmaceuticals, Inc. |
72%
|
suant to Chapter 34 Table of Contents 11 of the US Bankruptcy Code. The rights to crofelemer and the botanical extract used in Equilevia and Neonorm, as well as other intellectual property rights, we… |
| IRWD |
Ironwood Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from IRWD graph: Reciprocal relationship from JAGX graph: suant to Chapter 34 Table of Contents 11 of the US Bankruptcy Code. The rights to crofelemer and the botanical extrac… |
| BROWN-STONE-CAPITAL-LIMITED |
BROWN-STONE-CAPITAL-LIMITED |
62%
|
n our ability to execute on our business plan. Liquidity Management As of December 31, 2025, the Company is actively monitoring trends in its capital resources, recognizing favorable and unfavorable … |
| COMPANY-NAPO-NAPO-ACQUISITION-CORPORATION |
COMPANY-NAPO-NAPO-ACQUISITION-CORPORATION |
62%
|
fficient to allow Napo to sell its products at a profit. Healthcare Reform A primary trend in the US healthcare industry and elsewhere is cost containment. Government authorities and other third-part… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
have implemented, we should voluntarily delist from the Nasdaq Capital Market. If our common stock were delisted from Nasdaq voluntarily or involuntarily, trading of our Common Stock most likely will… |
| E-LLC |
E-LLC |
62%
|
fficient to allow Napo to sell its products at a profit. Healthcare Reform A primary trend in the US healthcare industry and elsewhere is cost containment. Government authorities and other third-part… |
| GLENMARK-LIFE-SCIENCES-LIMITED |
GLENMARK-LIFE-SCIENCES-LIMITED |
62%
|
. We are not aware of any FDA-approved drugs specifically acting as anti-secretory drugs to improve stool consistency. ORS, with or without antibiotics, is the current standard of care for infectious… |
| INDIA-BASED-ALIVUS-LIFE-SCIENCES-LIMITED |
INDIA-BASED-ALIVUS-LIFE-SCIENCES-LIMITED |
62%
|
. We are not aware of any FDA-approved drugs specifically acting as anti-secretory drugs to improve stool consistency. ORS, with or without antibiotics, is the current standard of care for infectious… |
| JAGX-HOLDINGS |
JAGX-HOLDINGS |
62%
|
y $15.3 million and $15.5 million for the years ended December 31, 2025 and 2024, respectively. These figures reflect revenue from the sale of our human drug Mytesi, our animal products branded as Ne… |
| MAGDALENA-BIOSCIENCES-INC |
MAGDALENA-BIOSCIENCES-INC |
62%
|
. For the years ended December 31, 2025 and 2024 , the Company paid Integrium approximately $ 0 and $ 505,000 , respectively. Asset Transfer and Transition Commitment On September 25, 2017, the Compa… |
| PATHEON-PHARMACEUTICALS-INC |
PATHEON-PHARMACEUTICALS-INC |
62%
|
ondition and location. Inventory is categorized into raw materials, work-in-process, and finished goods. Raw materials consist of CPL, recognized as inventory upon harvest and valued at cost, includi… |
| SEBELA-PHARMACEUTICALS-INC |
SEBELA-PHARMACEUTICALS-INC |
62%
|
suant to Chapter 34 Table of Contents 11 of the US Bankruptcy Code. The rights to crofelemer and the botanical extract used in Equilevia and Neonorm, as well as other intellectual property rights, we… |
| SHAMAN-PHARMACEUTICALS-INC |
SHAMAN-PHARMACEUTICALS-INC |
62%
|
ficant competition from other pharmaceutical companies, both for its currently approved indication and for planned follow-on indications, and our operating results will suffer if we fail to compete e… |
| STREETERVILLE-CAPITAL-LLC |
STREETERVILLE-CAPITAL-LLC |
62%
|
or any of our partners. Our future revenue stream will only come from one customer, Woodward, and will solely be dependent on the Manufacturing and Supply Agreement (as defined hereunder) with Woodwa… |
| TAKEDA-PHARMACEUTICALS-IRONWOOD-PHARMACEUTICALS- |
TAKEDA-PHARMACEUTICALS-IRONWOOD-PHARMACEUTICALS- |
62%
|
suant to Chapter 34 Table of Contents 11 of the US Bankruptcy Code. The rights to crofelemer and the botanical extract used in Equilevia and Neonorm, as well as other intellectual property rights, we… |
| UNITED-KINGDOM-BASED-VENTURE-LIFE-GROUP-PLC |
UNITED-KINGDOM-BASED-VENTURE-LIFE-GROUP-PLC |
62%
|
phylaxis in adult solid tumor patients receiving targeted therapies with or without standard chemotherapy. As previously announced, the top line results from the OnTarget study showed that the trial … |
| VENTURE-LIFE-GROUP-PLC |
VENTURE-LIFE-GROUP-PLC |
62%
|
any shall sell and dispense Mytesi directly ordered from the Company at the agreed price to patients within the territories identified in the agreement. The Company has entered into agreements with a… |
